The price you pay for weight loss medication in 2026 depends on a dizzying combination of factors: which drug, which format, your insurance plan, your employer's benefit design, manufacturer savings programs, and whether you're willing to navigate the system. This guide breaks down what the medications actually cost — list prices, real-world prices, and every savings pathway available.
List Prices vs. What People Actually Pay
The list price of most injectable GLP-1 medications is roughly $1,000–$1,350 per month. Almost nobody pays this. The gap between list price and actual out-of-pocket cost is where the confusion lives.
| Medication | List Price/Mo | With Insurance + Savings | Self-Pay Programs |
|---|---|---|---|
| Wegovy injection | ~$1,349 | $0–$25 (commercial) | $199–$349 via GoodRx/telehealth |
| Wegovy pill | ~$1,000+ | $0–$25 (commercial) | $149–$299 via NovoCare/telehealth |
| Wegovy HD 7.2mg | TBD | TBD | TBD (launched March 2026) |
| Zepbound | ~$1,060 | Varies widely | $299 via LillyDirect (KwikPen) |
| Foundayo | TBD | TBD | $149+ via LillyDirect |
| Saxenda | ~$1,400 | $25+ with savings card | Limited programs |
| Qsymia | ~$200–250 | $50–100 | ~$100–200 |
| Contrave | ~$300–400 | $50–100 | ~$100–200 |
Insurance Coverage: The Biggest Variable
Whether your insurance covers weight loss medication depends primarily on your employer's benefit design — not on the medication itself. About 36% of employers include anti-obesity medications as a covered benefit. The rest explicitly exclude them or cap coverage. Even within plans that cover GLP-1s, prior authorization is almost always required, and you'll typically need documented BMI, comorbidities, and evidence of prior lifestyle intervention.
Medicare: The GLP-1 Bridge
Medicare Part D historically could not cover medications prescribed for weight loss. The Treat and Reduce Obesity Act changed that, and the Medicare GLP-1 Bridge program launches July 1, 2026, covering Wegovy (all forms), Foundayo, and Zepbound KwikPen at a $50 monthly copay through December 2027.
Manufacturer Savings Programs
Novo Nordisk's savings card can bring commercially insured Wegovy costs as low as $25/month. Novo also launched a multi-month subscription program in March 2026 with fixed pricing through select telehealth providers. Eli Lilly offers similar programs through LillyDirect for Zepbound and Foundayo.
The Hidden Costs
Beyond the medication itself, budget for the prescriber consultation ($50–$200 for telehealth platforms), lab work (metabolic panel, A1c — $100–$300 if uninsured), and ongoing follow-up visits. Some telehealth platforms bundle these into a monthly membership fee.
The Bottom Line
The "real" cost of weight loss medication in 2026 ranges from $25/month (insured with savings card) to $349/month (self-pay through manufacturer programs). The $1,000+ list prices are what almost nobody actually pays.
Start by checking your insurance formulary. If coverage isn't available, manufacturer direct programs and telehealth partnerships offer the most predictable pricing. The oral options — Wegovy pill and Foundayo — tend to be less expensive than injectables at self-pay prices.